Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial

Ker, Katharine, Roberts, Ian, Chaudhri, Rizwana, Fawole, Bukola, Beaumont, Danielle, Balogun, Eni, Prowse, Danielle, Pepple, Tracey, Javaid, Kiran, Kayani, Aasia, Arulkumaran, Sabaratnam, Bates, Imelda ORCID: https://orcid.org/0000-0002-0862-8199 and Shakur-Still, Haleema (2018) 'Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial'. Trials, Vol 19, Issue 1, e712.

Preview

Text Ker_et_al-2018-Trials.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background: Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, most of which occur in low- and middle-income countries. Tranexamic acid (TXA) reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots. TXA decreases blood loss in surgery and reduces death due to
bleeding after trauma. When given within 3 h of birth, TXA reduces deaths due to bleeding in women with PPH. However, for many women, treatment of PPH is too late to prevent death. Over one third of pregnant women in the world are anaemic and many are severely anaemic. These women have an increased risk of PPH and suffer more severe outcomes if PPH occurs. There is an urgent need to identify a safe and effective way to reduce postpartum bleeding in anaemic women.
Methods/design: The WOMAN-2 trial is an international, multicentre, randomised, double-blind, placebo-controlled trial to quantify the effects of TXA on postpartum bleeding in women with moderate or severe anaemia. Ten thousand women with moderate or severe anaemia who have given birth vaginally will be randomised to receive 1 g of TXA or matching placebo by intravenous injection immediately (within 15 min) after the umbilical cord is cut or clamped. The primary outcome is the proportion of women with a clinical diagnosis of primary PPH. The cause of PPH will be described. Data on maternal health and wellbeing, maternal blood loss and its consequences, and other health outcomes will be collected as secondary outcomes. The main analyses will be on an ‘intention-to-treat’ basis, irrespective of whether the allocated treatment was received. Results will be presented as appropriate effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses will be based on the severity of anaemia (moderate versus severe) and type of labour (induced or augmented versus spontaneous). A study with 10,000 patients will have over 90% power to detect a 25% relative reduction from 10 to 7.5% in PPH. The trial will be conducted in hospitals in Africa and Asia.
Discussion: The WOMAN-2 trial should provide reliable evidence for the effects of TXA for preventing postpartum bleeding in women with anaemia.

Item Type:	Article
Subjects:	WQ Obstetrics > Pregnancy Complications > WQ 252 Hematologic complications WQ Obstetrics > Labor > WQ 300 General works WQ Obstetrics > Labor > WQ 330 Complications of labor WQ Obstetrics > WQ 500 Postnatal care
Faculty: Department:	Clinical Sciences & International Health > International Public Health Department
Digital Object Identifer (DOI):	https://doi.org/10.1186/s13063-018-3081-x
Depositing User:	Stacy Murtagh
Date Deposited:	23 Jan 2019 16:43
Last Modified:	22 Oct 2019 08:23
URI:	https://archive.lstmed.ac.uk/id/eprint/10031

Statistics

View details

Actions (login required)

Edit Item